JP2019535791A5 - - Google Patents

Info

Publication number

JP2019535791A5

JP2019535791A5 JP2019528540A JP2019528540A JP2019535791A5 JP 2019535791 A5 JP2019535791 A5 JP 2019535791A5 JP 2019528540 A JP2019528540 A JP 2019528540A JP 2019528540 A JP2019528540 A JP 2019528540A JP 2019535791 A5 JP2019535791 A5 JP 2019535791A5

Authority

JP

Japan

Prior art keywords

composition according

subject

risk

reduce

insulin

Prior art date

2017-11-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims 18
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
• 208000013016 Hypoglycemia Diseases 0.000 claims 5
• 108090001061 Insulin Proteins 0.000 claims 5
• 102000004877 Insulin Human genes 0.000 claims 5
• 230000002218 hypoglycaemic effect Effects 0.000 claims 5
• 229940125396 insulin Drugs 0.000 claims 5
• 229960004225 insulin degludec Drugs 0.000 claims 5
• 208000024172 Cardiovascular disease Diseases 0.000 claims 4
• FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims 4
• 108010050259 insulin degludec Proteins 0.000 claims 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
• 239000008103 glucose Substances 0.000 claims 3
• 238000012544 monitoring process Methods 0.000 claims 3
• 238000011282 treatment Methods 0.000 claims 3
• 230000002411 adverse Effects 0.000 claims 2
• 230000007211 cardiovascular event Effects 0.000 claims 2
• 206010012601 diabetes mellitus Diseases 0.000 claims 2
• 230000002641 glycemic effect Effects 0.000 claims 2
• 239000005022 packaging material Substances 0.000 claims 2
• 208000019553 vascular disease Diseases 0.000 claims 2
• 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
• 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
• 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
• 206010027525 Microalbuminuria Diseases 0.000 claims 1
• 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
• 210000003423 ankle Anatomy 0.000 claims 1
• 239000003472 antidiabetic agent Substances 0.000 claims 1
• 229940125708 antidiabetic agent Drugs 0.000 claims 1
• 230000036772 blood pressure Effects 0.000 claims 1
• 208000026106 cerebrovascular disease Diseases 0.000 claims 1
• 208000020832 chronic kidney disease Diseases 0.000 claims 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
• 238000002648 combination therapy Methods 0.000 claims 1
• 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 1
• 238000011866 long-term treatment Methods 0.000 claims 1
• 239000003538 oral antidiabetic agent Substances 0.000 claims 1
• 230000002028 premature Effects 0.000 claims 1
• 201000001474 proteinuria Diseases 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
• 230000002861 ventricular Effects 0.000 claims 1